Cytokines, Genetic Lesions and Signaling Pathways in Anaplastic Large Cell Lymphomas

被引:1
|
作者
Merlio, Jean-Philippe [1 ,2 ]
Kadin, Marshall E. [3 ,4 ]
机构
[1] Ctr Hosp & Univ Bordeaux, Tumor Biol & Tumor Bank Lab, F-33600 Pessac, France
[2] Univ Bordeaux, INSERM U1053, F-33000 Bordeaux, France
[3] Brown Univ, Dept Pathol & Lab Med, Alpert Sch Med, Providence, RI 02903 USA
[4] Boston Univ, Dept Dermatol, Boston, MA 02215 USA
关键词
anaplastic large cell lymphoma; oncogenesis; cytokine; signaling pathways; CD30(+) LYMPHOPROLIFERATIVE DISORDERS; T-CELL; BRENTUXIMAB VEDOTIN; HODGKIN-LYMPHOMA; TP63; REARRANGEMENTS; CUTANEOUS LYMPHOMA; ALK; EXPRESSION; KINASE; ACTIVATION;
D O I
10.3390/cancers13174256
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary This review summarizes the main features of anaplastic large cell lymphoma (ALCL) subtypes focusing on activated biological pathways that may have clinical significance for diagnosis, prognosis and personalized therapy. ALCL is a tumor of activated T cells and possibly innate lymphoid cells with several subtypes according to clinical presentation and genetic lesions. On one hand, the expression of transcription factors and cytokine receptors triggers signaling pathways. On the other hand, ALCL tumor cells also produce many proteins including chemokines, cytokines and growth factors that affect patient symptoms. Examples are accumulation of granulocytes stimulated by IL-8, IL-17, IL-9 and IL-13; epidermal hyperplasia and psoriasis-like skin lesions due to IL-22; and fever and weight loss in response to IL-6 and IFN-gamma. In this review, we focus on the biology of the main ALCL subtypes as the identification of signaling pathways and ALCL-derived cytokines offers opportunities for targeted therapies.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma
    Lai, Chao-Ming
    Horowitz, Sandra
    EXPERT REVIEW OF HEMATOLOGY, 2013, 6 (04) : 361 - 373
  • [22] Adult's anaplastic CD30+ large cell lymphomas
    Cany, L
    Soubeyran, P
    Boulanger, V
    Soubeyran, I
    Richaud, P
    Eghbali, H
    Hoerni, B
    BULLETIN DU CANCER, 1999, 86 (09) : 739 - 744
  • [23] Breast implants and anaplastic large cell lymphomas among females in the California Teachers Study cohort
    Wang, Sophia S.
    Deapen, Dennis
    Voutsinas, Jenna
    Lacey, James V., Jr.
    Lu, Yani
    Ma, Huiyan
    Clarke, Christina A.
    Weisenburger, Dennis
    Forman, Stephen J.
    Bernstein, Leslie
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (03) : 480 - 483
  • [24] Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas
    Di Napoli, Arianna
    De Cecco, Loris
    Piccaluga, Pier Paolo
    Navari, Mohsen
    Cancila, Valeria
    Cippitelli, Claudia
    Pepe, Giuseppina
    Lopez, Gianluca
    Monardo, Francesca
    Bianchi, Antonella
    D'Amore, Emanuele Stefano Giovanni
    Gianelli, Umberto
    Facchetti, Fabio
    Berti, Emilio
    Bhagat, Govind
    MODERN PATHOLOGY, 2019, 32 (02) : 216 - 230
  • [25] Lymphohistiocytic anaplastic large cell lymphoma involving skin: A diagnostic challenge
    Chuang, Shih-Sung
    Hsieh, Yen-Chuan
    Ye, Hongtao
    Hwang, Wei-Shou
    PATHOLOGY RESEARCH AND PRACTICE, 2009, 205 (04) : 283 - 287
  • [26] In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas
    Passoni, Lorena
    Gallo, Barbara
    Biganzoli, Elia
    Stefanoni, Roberta
    Massimino, Maura
    Di Nicola, Massimo
    Gianni, Alessandro M.
    Gambacorti-Passerini, Carlo
    HAEMATOLOGICA, 2006, 91 (01) : 48 - 55
  • [27] ALK-positive anaplastic large-cell lymphoma: strong T and B anti-tumour responses may cause hypocellular aspects of lymph nodes mimicking inflammatory lesions
    Borisch, B
    Yerly, S
    Cerato, C
    Schwaller, J
    Wacker, P
    Ozsahin, AH
    Brousse, N
    Hoessli, DC
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (04) : 243 - 249
  • [28] Anaplastic Large Cell Lymphomas: ALK Positive, ALK Negative, and Primary Cutaneous
    Xing, Xiaoming
    Feldman, Andrew L.
    ADVANCES IN ANATOMIC PATHOLOGY, 2015, 22 (01) : 29 - 49
  • [29] EFFICACY OF THERAPY OF DIFFERENT VARIANTS OF ANAPLASTIC LARGE T-CELL LYMPHOMAS
    Vinogradova, Yu. E. y
    Lutsenko, I. N.
    Kaplanskaya, I. B.
    Vorobyev, I. A.
    Samoilova, R. S.
    Gorgidze, L. A.
    Ryzhkova, N. A.
    Valiev, T. T.
    Gilyazitdinova, E. A.
    Dzhulakyan, U. L.
    Egorova, E. K.
    Zvonkov, E. E.
    Krasilnikova, B. B.
    Magomedova, A. U.
    Margolin, O. V.
    Maryin, D. S.
    Kremenetskaya, A. M.
    Kravchenko, S. K.
    Vorobyev, A. I.
    TERAPEVTICHESKII ARKHIV, 2008, 80 (07) : 33 - 37
  • [30] A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas
    Dukers, DF
    ten Berge, RL
    Oudejans, JJ
    Pulford, K
    Hayes, D
    Miseré, JFMM
    Ossenkoppele, GJ
    Jaspars, LH
    Willemze, R
    Meijer, CJLM
    JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (02) : 129 - 136